Longitudinal characterization of the mumps-specific HLA-A2 restricted T-cell response after mumps virus infection
Publication date
2021-12
Editors
Advisors
Supervisors
Document Type
Article
Metadata
Show full item recordCollections
License
cc_by
Abstract
Waning of the mumps virus (MuV)-specific humoral response after vaccination has been suggested as a cause for recent mumps outbreaks in vaccinated young adults, although it cannot explain all cases. Moreover, CD8+ T cells may play an important role in the response against MuV; however, little is known about the characteristics and dynamics of the MuV-specific CD8+ T-cell response after MuV infection. Here, we had the opportunity to follow the CD8+ T-cell response to three recently identified HLA-A2*02:01-restricted MuV-specific epitopes from 1.5 to 36 months post-MuV infection in five previously vaccinated and three unvaccinated individuals. The infection-induced CD8+ T-cell response was dominated by T cells specific for the ALDQTDIRV and LLDSSTTRV epitopes, while the response to the GLMEGQIVSV epitope was subdominant. MuV-specific CD8+ T-cell frequencies in the blood declined between 1.5 and 9 months after infection. This decline was not explained by changes in the expression of inhibitory receptors or homing markers. Despite the ongoing changes in the frequencies and phenotype of MuV-specific CD8+ T cells, TCRβ analyses revealed a stable MuV-specific T-cell repertoire over time. These insights in the maintenance of the cellular response against mumps may provide hallmarks for optimizing vaccination strategies towards a long-term cellular memory response.
Keywords
MMR vaccination, Mumps infection, T-cell immunity, Immunology, Pharmacology, Drug Discovery, Infectious Diseases, Pharmacology (medical)
Citation
Lanfermeijer, J, Nühn, M M, Emmelot, M E, Poelen, M C M, van Els, C A C M, Borghans, J A M, van Baarle, D, Kaaijk, P & de Wit, J 2021, 'Longitudinal characterization of the mumps-specific HLA-A2 restricted T-cell response after mumps virus infection', Vaccines, vol. 9, no. 12, 1431. https://doi.org/10.3390/vaccines9121431